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Protocol
AbstrACt
background Identifying simple, low-cost and scalable 
means of supporting lifestyle change and medication 
adherence for patients following a cardiovascular (CV) 
event is important.
Objective The TEXTMEDS (TEXT messages to improve 
MEDication adherence and Secondary prevention) study 
aims to investigate whether a cardiac education and 
support programme sent via mobile phone text message 
improves medication adherence and risk factor levels in 
patients following an acute coronary syndrome (ACS).
study design A single-blind, multicentre, randomised 
clinical trial of 1400 patients after an ACS with 12 months 
follow-up. The intervention group will receive multiple weekly 
text messages that provide information, motivation, support 
to adhere to medications, quit smoking (if relevant) and 
recommendations for healthy diet and exercise. The primary 
endpoint is the percentage of patients who are adherent 
to cardioprotective medications and the key secondary 
outcomes are mean systolic blood pressure (BP) and low-
density lipoprotein cholesterol. Secondary outcomes will also 
include total cholesterol, mean diastolic BP, the percentage 
of participants who are adherent to each cardioprotective 
medication class, the percentage of participants who achieve 
target levels of CV risk factors, major vascular events, 
hospital readmissions and all-cause mortality. The study will 
be augmented by formal economic and process evaluations 
to assess acceptability, utility and cost-effectiveness.
summary The study will provide multicentre randomised 
trial evidence of the effects of a text message-based 
programme on cardioprotective medication adherence and 
levels of CV risk factors.
Ethics and dissemination Primary ethics approval was 
received from Western Sydney Local Health District Human 
Research Ethics Committee (HREC2012/12/4.1 (3648) AU 
RED HREC/13/WMEAD/15). Results will be disseminated 
via peer-reviewed publications and presentations at 
international conferences.
trial registration number ACTRN12613000793718; Pre-
results.
IntrOduCtIOn
Cardiovascular disease (CVD) is the leading 
burden of premature death and disease glob-
ally.1 About half of the patients who have 
had a prior hospital admission for coro-
nary heart disease (CHD) will have a recur-
rent event.2 If survivors of acute coronary 
syndrome (ACS) attend secondary preven-
tion programme,3 4 adhere to risk factor 
modification and are compliant with drug 
strengths and limitations of this study
 ► This is a multicentre trial that will provide the 
evidence for effectiveness of text  messaging 
programme and their generalisability above existing 
trial evidence from single-centre studies.
 ► The intervention development follows a previously 
published process, the messages are based on 
psychological behaviour change theory and the 
message management is via a custom-built 
computerised programme.
 ► Alongside this study, we have included an economic 
evaluation study and process evaluation.
 ► This is a study conducted across multiple centres of 
Australia only and uses English text only.
 ► The primary and key secondary study outcomes 
are surrogate outcome  measures and not hard 
clinical outcome measures such as major adverse 
cardiovascular events.
 o
n
 14 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019463 on 27 January 2018. Downloaded from 
2 Chow CK, et al. BMJ Open 2017;8:e019463. doi:10.1136/bmjopen-2017-019463
Open Access 
regimens,5–7 their hospital readmissions within 1 year may 
be reduced and their survival improved.8 9 
Despite the overwhelming evidence of the effectiveness 
of secondary prevention programmes underwritten by 
guidelines,10 11 surveys from multiple countries demon-
strate gaps in uptake of cardioprotective medications 
and lifestyle recommendations.12 13 The WHO report in 
2003 highlighted medication non-adherence as a global 
concern,14 and the World Heart Federation have identi-
fied secondary CVD prevention as a public health priority 
and key to achieving WHO’s target of 30% reduction in 
premature mortality from non-communicable diseases by 
2030.15
A number of interventions can improve adherence 
to cardioprotective medications among patients with 
CHD, and simple interventions, including text message 
reminders, have similar effectiveness to more complex 
interventions in improving adherence.16 Text message-
based interventions have gained increasing traction as a 
potential low-cost means of providing self-management 
support to patients seeking to change health behaviours. 
This increase has been driven by an accumulating body 
of research evidence17–23 as well as the global reach of 
mobile phones.24 A systematic review and meta-analysis of 
16 studies of text message-based interventions to support 
medication adherence among patients with chronic 
diseases demonstrated that text messaging approxi-
mately doubles the odds of medication adherence (OR 
2.11, 95% CI 1.52 to 2.93; P<0.001). There are important 
limitations of the current literature; however, including 
small sample sizes (median sample size 97, range 21–538), 
significant heterogeneity and short duration follow-up 
(median intervention duration 12 weeks, range 4–48 
weeks).25
It is in this context that we developed the TEXT messages 
to improve MEDication adherence and Secondary 
prevention (TEXTMEDS) study. TEXTMEDS is a multi-
centre randomised clinical trial of patients with ACS to 
determine the effect of a semipersonalised secondary 
prevention programme delivered via mobile phone text 
messages on medication adherence, blood pressure (BP), 
low-density lipoprotein (LDL)-cholesterol and other clin-
ical outcome measures in patients after an ACS.
MEthOds And AnAlysIs
study design
TEXTMEDS is a single-blind, multicentre, randomised 
controlled trial delivering a 12-month secondary preven-
tion programme via text messages to patients with ACS 
(figure 1). The recruitment sites include 15 public 
hospitals in urban and rural Australia that serve ethni-
cally, culturally and socioeconomically diverse commu-
nities. The target sample size is 1400 patients with a 
confirmed diagnosis of ACS. Participants are randomly 
allocated to either control or intervention group. The 
control group is assigned to receive standard care as 
determined by their treating physician. The intervention 
group is allocated to receive, in addition to standard 
care, multiple weekly text messages that provide infor-
mation, motivation and support for medication adher-
ence, smoking cessation (if relevant), recommendations 
for healthy diet and exercise and other cardiac preven-
tion advice. Trained research personnel blinded to the 
group allocation conduct assessments at baseline and 12 
months during a face-to-face interview and at 6 months 
over phone. Further data will be obtained via extraction 
of linked data available with consent from government 
repositories. The study will be augmented by formal 
economic and process evaluations to assess acceptability, 
utility and cost-effectiveness of the intervention. This 
study will be monitored and managed centrally with 
periodic site monitoring visits.
randomisation and blinding
After obtaining written informed consent, the data are 
entered by the site coordinator into a web-based case 
record form (CRF) and then randomisation occurs via 
a centralised, computerised randomisation programme 
in a uniform 1:1 allocation ratio. The text message 
programme is initiated after the patient is discharged 
from the hospital and the patients (but not their care 
providers, research personnel or investigators) are 
informed of their allocation through a single text message. 
Study coordinators and research assistants conducting 
the assessments and statisticians will be blinded. This 
randomisation programme is electronically linked to 
the software programme that delivers the text message 
intervention, thereby minimising need for human inter-
ference. Key participant characteristics that determine 
text message customisation and personalisation are also 
automatically imported into software administering the 
intervention.
study population
Patients with a confirmed diagnosis of ACS are eligible 
for the study. ACS is defined based on one of the two 
following criteria:
1. Acute myocardial infarction consistent with the Third 
Universal definition of myocardial ischaemia (MI)26: 
Detection of rise and/or fall of cardiac troponin with 
at least one value above the 99th percentile of the up-
per reference limit together with evidence of MI with 
at least one of the following: (1) symptoms of isch-
aemia; (2) ECG changes indicative of new ischaemia; 
(3) development of pathological Q waves on ECG or 
(4) imaging evidence of new loss of viable myocardi-
um or new regional wall motion abnormality.
2. Patients admitted to hospital acutely with symptoms 
typical of cardiac ischaemia not meeting the above 
criteria and one of the following indicators of coro-
nary artery disease: (1) new or known coronary angio-
graphic evidence of coronary disease (coronary artery 
narrowing of ≥50% of at least one major vessel) or (2) 
prior coronary artery bypass graft surgery or (3) prior 
percutaneous coronary intervention.
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Patients must also meet the following inclusion criteria: 
(1) ability to provide informed consent, (2) own an oper-
ational mobile telephone and (3) can read text messages 
in English on a mobile phone and (4) life expectancy 
more than 6 months. For those people who are ineligible 
or decline to participate, a ‘screening log’ of basic demo-
graphic information and reasons for non-participation is 
maintained.
Control group
The control group will receive standard care post-ACS as 
determined by their usual doctors. This generally includes 
secondary prevention cardiovascular (CV) medications 
and referral to a centre-based cardiac rehabilitation or 
other secondary prevention programme.
Intervention
The intervention group will receive standard care (as 
described above), plus an additional support package 
that includes a series of text messages focusing on medi-
cation adherence and lifestyle modification as well as an 
opportunity to communicate with an English-speaking 
health counsellor over a 12-month period as detailed 
below.
Figure 1 Flow chart of study design. Patients with acute coronary syndromes are considered for inclusion in the study 
and randomisation is single blind, with allocation determined by computerised programme and initiated by computerised 
programme after discharge from hospital. ACS, acute coronary syndrome; CV, cardiovascular; LDL, low-density 
lipoprotein; TEXTMEDS, TEXT messages to improve MEDication adherence and Secondary prevention.
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Message content, frequency, sequence
The text message intervention builds on our previous 
experience in developing text message interventions from 
the TEXT ME study.17 We have previously described the 
process of message content development,27 as well as the 
details of the intervention and its delivery, including the 
similarities and differences of the TEXT ME and TEXT-
MEDS study in a separate manuscript.28 For TEXTMEDS, 
the majority of text messages providing information and 
support on lifestyle modification are from the TEXT 
ME study,17 and in addition, participants receive weekly 
support from a bank of text messages, we developed with 
a focus on CV secondary preventative medications and 
barriers/enablers to medication adherence.29 30 This 
included information about the drug’s mechanism of 
action, research evidence as well as common side effects, 
and provided motivation, including tips and reminders to 
improve medication adherence. The programme is struc-
tured such that education on medications is suitable for 
low health literacy at the start and increases in complexity 
during the course of the programme. Each participant 
receives a customised and personalised set of messages 
(box). Thus messages are ‘customised’ by selecting 
content relevant to participant characteristics such as 
medication class prescription, dietary habits (vegetarian 
or non-vegetarian) and/or smoking status. Messages are 
‘personalised’ as the preferred name of the participant 
is incorporated into some messages using a mail-merge 
type of function. Participants receive two to four messages 
per week, receiving fewer messages during mid-study. 
The messages will be sent at random working hours on 
random weekdays. Each message will have a unique signa-
ture (study and hospital name) to ensure that participants 
know these messages are from the TEXTMEDS study and 
participants at baseline will be given a brief training on 
how to read, delete and save a text message and unsub-
scribe if required. Participants can also update their 
key information, for example, mobile phone number, 
change in smoking status or types of medications through 
the course of the study and this will be reflected in the 
ongoing text messages they receive. Messages are sent 
at no cost to the participants and a bulk-rate cost to the 
study. Differently to the TEXT ME study,17 the TEXT-
MEDS intervention was designed to encourage two-way 
communication. Thus, once a month, participants allo-
cated to the intervention are sent a message encouraging 
them to text the health counsellor to ask questions or 
request additional information.
Role of the health counsellor
A health counsellor located at the coordinating centre 
monitors and responds to participants’ replies from across 
Australia either via text message or phone call within 3 
working days.28 The health counsellor has health profes-
sional qualifications (eg, nurse or dietitian) and is given 
specific training to respond to patients’ requests and 
provide further guidance using an intervention manual 
we have developed for the study. The health counsellor is 
assisted as required by a clinical research fellow (cardiolo-
gist or cardiology subspecialty trainee and clinicians from 
the study investigator team). All replies and responses are 
reviewed in regular weekly team meetings.
Message management system
The TEXTMEDS message management system is a more 
sophisticated version of the original TEXT ME software 
programme used to deliver the TEXT ME intervention. 
In brief, it uses a web interface to enable the simultaneous 
entry of data from multiple study centres. Key partic-
ipant characteristics are automatically imported from 
electronic databases into the software administering the 
intervention to customise and personalise messages. The 
programme is configured to run a series of background 
checks to ensure data accuracy, integrity and system func-
tioning. A detailed log of all transactions with partici-
pants, including delivery reports, participants’ replies 
and health counsellor’s interactions is maintained.
data collection and study outcomes
The follow-up study assessments will occur at 6 months 
over phone and 12 months in-person. The primary 
outcome of medication adherence to cardioprotective 
box Examples of text messages sent to the intervention 
group27 31
Introductory message
Hi <NAME>, Welcome to TEXT messages to improve MEDication 
adherence and Secondary prevention (TEXTMEDS). We hope you enjoy 
the messages. If you have received this in error respond STOP to opt 
out. TEXTMEDS <NAME> Hospital.
Medication-related messages
Hi <NAME> are you still taking your medications every day? Keep it 
up!
Aspirin stops the blood platelets from sticking & prevents blood clots 
forming <NAME> take aspirin once per day with food.
You may be on Angiotensin Receptor Blockers (names end in artan) 
they help lower BP
Remember _ cholesterol & blood pressure lowering tablets need to be 
taken every day
lifestyle-related messages
Check out www.heartfoundation.org.au for tips & info about preventing 
heart disease
Hi <NAME>, why not try and use the stairs instead of the lift
Try steaming, baking or BBQ to reduce the need for excess oil when 
cooking
<Name>, try identifying the triggers that make you want a cigarette & 
avoid them
two-way communication messages
Do you have any questions for our health counsellor <NAME>? Text us 
your question and we will contact you shortly.
Final message
This is your last message from TEXTMEDS. Best wishes from ALL of 
us. We hope that you enjoyed the messages over the past 12 months.
BBQ, Barbeque; BP, blood pressure.
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messages will be the difference between intervention and 
control groups in the percentage of patients adherent to 
all five classes of recommended cardioprotective medi-
cations (unless contraindicated/previously documented 
intolerance). The five cardioprotective classes of medi-
cations are: (1) angiotensin-converting enzyme inhibitor 
or angiotensin II receptor blockers, (2) beta-blocker, (3) 
statin lipid-lowering, (4) aspirin and (5) ADP receptor 
antagonist. Medication adherence will be measured by 
asking participants on how many days in the past 30 days 
they missed a particular class of medication for each of 
the five classes of medications indicated and this is asked 
at both 6-month and 12-month visits. Patients will be 
defined as adherent if they report that they have taken 
their indicated medications on >80% of days (>24/30 
days) at both 6-month and 12-month visits.19 Indicated 
medications will be all five classes of guideline recom-
mended medications listed above unless a contraindica-
tion is documented in their case report forms.
The key secondary outcomes are the difference between 
intervention and control groups at 12 months for LDL-cho-
lesterol level and systolic BP (raised BP). Other secondary 
outcomes include: total cholesterol, diastolic BP, the 
proportion of participants adherent to each medication 
class, other CV risk factors including behavioural risk 
factors, psychosocial factors, major CV events, hospital 
readmissions and all-cause mortality and composites of 
risk factor control and major adverse CV events (table 1). 
A formal endpoint adjudication process will be imple-
mented and includes a review of original documents 
for major CV events, hospital readmissions and deaths by 
two independent adjudicators. The adjudication process 
is overseen by KS. Serious adverse events will be collected 
by the investigator/research coordinator from randomisa-
tion to 30 days after the end-of-study visit and reported to 
the central coordinating centre as well as to ethics as per 
local guidelines. To optimise follow-up, multiple attempts 
will be made to contact participants including contacting 
their referring doctor and at a minimum we will aim to 
record vital status for all participants.
Data management is via a secure clinical trial data 
management system managed by The George Institute 
(TGI) with data entry through a password protected, 
web-based interface by registered staff, real-time data 
query generation for values entered outside of preset 
valid ranges and consistency checking. The steering 
committee (chaired by CC) has the overall responsibility 
for execution of the study.
Table 1 Study outcomes
Outcome Assessment Baseline 6 month 12 month
Primary outcome
  Medication adherence Proportion of patients that are adherent to five out of five 
indicated medications (or four of four, if five not indicated). 
Adherence defined as taking medications on >24/30 days 
for all medicines at two time points of 6, 12 months.19
✓ ✓
Key secondary outcomes
  Systolic BP Average of two resting, sitting digital recordings ✓ ✓
  LDL-cholesterol Fasting blood sample ✓ ✓
Secondary outcomes
  Medication adherence Proportion of patients adherent to the separate drug 
classes
✓ ✓
  Diastolic BP Average of two resting, sitting digital recordings ✓ ✓
  Total cholesterol Fasting blood sample ✓ ✓
  Smoking Self-report ✓ ✓
  Obesity Weight, height, waist and hip circumference ✓ ✓
  Physical activity General Physical Activity Questionnaire42 ✓ ✓
  Fruit and vegetable 
intake
WHO Steps instrument43 ✓ ✓
  Anxiety symptoms Generalised Anxiety Disorder 7-item scale44 ✓
  Depressive symptoms Patient Health Questionnaire45 ✓
  Quality of life SF-12_V2 Health Survey35 ✓ ✓
  CV events CV death, non-fatal AMI, stroke or hospital admission with 
unstable angina or congestive heart failure
✓ ✓
  All-cause mortality Data linkage ✓ ✓
AMI, acute myocardial infarction; BP, blood pressure; CV, cardiovascular; LDL, low-density lipoprotein.
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Process measures
Process evaluations explore the implementation, receipt 
and setting of an intervention and assist in the interpreta-
tion of outcome results.32 Analyses will be informed by the 
Pawson and Tilley realistic evaluation model,33 which is an 
approach grounded in realism that considers social, indi-
vidual, contextual and material contributions to change. 
We will use mixed methods to investigate why the TEXT-
MEDS strategy may or may not have been effective and 
which intervention components were most influential.
The process evaluation will include a semiquantitative 
survey and focus groups with intervention participants. All 
participants receiving the intervention will be invited to 
complete a written questionnaire assessing their percep-
tions, experience and the degree of engagement with 
the intervention at the completion of the trial. The ques-
tionnaire will comprise a combination of closed 5-point 
Likert scale and open questions. A sample of the inter-
vention group participants will be invited to participate 
in focus groups on perceptions of the utility and accept-
ability of the intervention programme. To obtain a broad 
range of views we will use a maximum variation sampling 
method based on patient characteristics such as gender 
and site. Sampling will continue until thematic saturation 
is reached; however, we anticipate approximately four 
focus groups will be needed. An in-depth interview will 
also be conducted with the health counsellor to under-
stand his/her perceptions of patients’ engagement with 
the programme. Focus groups and the health counsellor 
interview will be conducted by a trained qualitative inter-
viewer, digitally recorded and transcribed. Analyses will 
be thematic and coding based on emergent themes.
Economic analysis
The costs and health outcomes associated with the inter-
vention will be compared in an incremental cost-effective-
ness analysis. A health sector perspective will be adopted. 
The costs of delivering the intervention will be assessed by 
measuring and valuing the incremental resources used.34 
Hospitalisations will be collected at each follow-up. 
Consent will be sought for access to individual participant 
Medical Benefits Schedule and Pharmaceutical Bene-
fits Scheme claims usage through Medicare Australia to 
ascertain use of medical services and prescribed pharma-
ceuticals. Changes to health benefits will be assessed using 
quality-adjusted life years (QALYs). These will be assessed 
using the 12-item Short Form Survey Version 2 (SF-12_V2) 
Health Survey35 (License Number QM024287). Although 
we do not expect significant differences in survival or 
quality of life between treatment groups within trial, 
these data are needed to provide an estimate of the base-
line quality of life in this patient population. Given the 
likely small numbers of CV events occurring within the 
trial, the quality of life and costs data collected in trial will 
need to be modelled using data on quality of life and cost 
associated with CV events from literature review.36 Long-
term costs and QALYs will be modelled using a decision 
analytic Markov model that will enable us to extrapolate 
beyond the data collection period, predict within the 
cohort the occurrence of CV events over a lifetime and 
thus estimate longer-term costs, potential cost savings and 
benefits of the intervention.37
statistical considerations
A 10% improvement in the proportion taking appropriate 
secondary prevention is considered to be a clinically 
meaningful increase and associated with a decrease in 
short-term mortality.38 To test for a 10% improvement in 
the primary outcome relative risk (RR of 1.10) in the treat-
ment compared with the control arm (assuming ~70% of 
patients are taking appropriate secondary prevention in 
control arm, based on contemporary Australian registry 
data,39 40 and this would rise to 77% in the interven-
tion arm) with 80% power (type I error=5%, two-sided 
test), we would require a total sample size of 1246, 
rising to ~1396 accounting for a ~10% loss to follow-up. 
This sample size of 1246 would enable us to also detect 
with 80% power a minimum detectable difference in 
secondary outcomes of (1) 0.15 mmol/L in LDL-choles-
terol assuming a SD of 0.92 mmol/L,41 (2) 2.7 mm Hg 
in systolic BP, assuming an SD of 17 mm Hg41 and a 
minimum detectable RR of 0.69 in CV events assuming a 
major CV event rate of 19% or a power of approximately 
13% to detect a RR of 0.80 in CV events, assuming a lower 
CV event rate of 5% at 12 months from contemporary 
Australian data.
The intention to treat principle will be used and 
patients will be analysed according to the group to which 
they are allocated. A detailed statistical analysis plan will 
be prepared prior to the analysis. The primary outcome 
will be compared between groups using the χ2 test. The 
primary analysis will be unadjusted. The mean level of 
BP and cholesterol will be analysed using an analysis of 
covariance using the baseline values as the covariate with 
estimation of the mean difference and corresponding 
95% CI. For each of the secondary outcome measures, 
parameters will be compared between the two groups 
with relevant statistical tests providing mean difference 
for continuous variables or RRs for dichotomous vari-
ables along with the 95% CIs and two-sided P values.
We will also analyse effects across subgroups, such as sex 
and age, using logistic regression models with treatment 
group, subgroup and subgroup by treatment interaction 
as fixed effects. Number of patients with major CV events 
will be compared between treatments using a χ2 test. The 
criterion for statistical significance will be set at α=0.05. 
Number needed to treat will also be calculated and its 
95% CI for the primary outcome.
Ethics and dissemination
The findings of this study will be disseminated via the usual 
scientific forums including peer-reviewed publications 
and presentations at international conferences. The study 
is sponsored by The George Institute for Global Health at 
the University of Sydney, and centrally coordinated and 
managed by staff based mainly at Westmead Hospital 
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and the George Institute. The design and conduct of 
the study is overseen by a Steering Committee (authors 
and some site principle investigators). This committee 
has expertise in large-scale clinical trials and qualitative 
research, economic analysis, clinical CVD management 
and healthy policy implementation. This study will adhere 
to the Australian National Health and Medical Research 
Council ethical guidelines for human research. Formal 
ethical approval for this study has been obtained from 
Western Sydney Local Health District Human Research 
Ethics Committee (HREC2012/12/4.1 (3648) AU RED 
HREC/13/WMEAD/15). The current protocol is V.3.0 
(31 October 2013). Any changes in the protocol during 
the trial that may affect the conduct of the trial, safety, 
and the benefit to patients will require a formal amend-
ment to the protocol. Written and informed consent will 
be obtained from all participants.
dIsCussIOn And COnClusIOn
The TEXTMEDS study will evaluate an innovative means 
of delivering a cardiac prevention programme to survi-
vors of an ACS event and whether it improves important 
cardiac prevention targets in this patient population 
including medication adherence and risk factor levels. 
While text message-based programme are not new, what 
makes them innovative in the space of cardiac preven-
tion is their now massive reach, given that mobile phone 
ownership approaches 100% in many countries and they 
all receive text.
The focus of this study on medication adherence is 
due to its very large and important role as a component 
of post-ACS prevention. Improving medical adherence 
to cardioprotective medicines has been shown to reduce 
CV morbidity and mortality. One challenge; however in 
this area, is the optimal means of measuring medical 
adherence. There are no gold standard measures of 
adherence and self-reported measures are the most 
well-accepted and practical means of measuring adher-
ence in clinical trials. We acknowledge that self-re-
ported measures can overestimate adherence, but this 
should not impact the difference in adherence between 
the intervention and control groups. To get an objec-
tive measure of the impact of the intervention, key 
outcomes for this trial will also be LDL-cholesterol and 
BP, which are both strong and objective measures of CV 
risk. We will also be examining the impact of the inter-
vention programme on behavioural risk factors, which 
our predecessor study to this, TEXT ME, demonstrated 
a substantial impact.
In our previous single-centre study—TEXT ME, our 
group has demonstrated that a lifestyle-focused text-mes-
saging programme was associated with reductions in 
LDL-cholesterol, BP, body mass index and smoking, 
and with increases of physical activity levels. TEXT ME 
also demonstrated that participants in the intervention 
group were more likely to achieve risk factor control 
for multiple risk factors with 28.9% in the intervention, 
versus 10.3% in the control group achieving target 
levels of 4 or more key risk factors (RR 2.80, 95% CI 
1.95 to 4.02).17 The TEXTMEDS study will extend the 
knowledge from the TEXT ME study by examining the 
impact of a longer text message programme (12 months 
vs 6 months) and delivered across multiple urban and 
rural hospitals in a range of socioeconomically varied 
contexts across the breadth of Australia. By involving 
a health counsellor to track and respond to messages, 
TEXTMEDS will also provide information on whether 
interactivity is regarded as important by participants.
A cardiac prevention programme delivered via text 
messages has the advantages of low cost and being easily 
automated. These elements can allow these programmes 
to reach large numbers of people, including those in 
resource-poor settings and in geographically isolated 
communities, and therefore, the potential to have a 
substantial population impact.
In conclusion, the TEXTMEDS study will provide multi-
centre randomised controlled data on whether a cardiac 
prevention programme delivered to support cardiac 
prevention across multiple hospital sites is of utility and 
effective in improving targets of cardiac prevention in 
patients post- ACS.
reporting and dissemination
Results of this study will be presented at national meet-
ings and published in a scientific journal. Participants will 
not be individually notified regarding the results of this 
study.
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